Healthcare Architecture Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Description
Healthcare Architecture Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Healthcare Architecture Market
The global healthcare architecture market size was valued at USD 8.52 billion in 2023 and is projected to grow from USD 8.89 billion in 2024 to USD 13.21 billion by 2032, exhibiting a CAGR of 5.1% during the forecast period of 2024-2032.
The pandemic has pushed changes in healthcare architecture, specializing in infection manage, flexible spaces, and telemedicine integration. There's an improved call for for brand spanking new and upgraded centers, particularly outpatient facilities, with an emphasis on sustainability and resilience. Updated policies have an effect on design requirements, even as price range constraints necessitate fee-effective answers.
The healthcare structure marketplace has pushed the way of the need for better infection control, the mixing of telemedicine, and the creation of bendy, adaptable areas. Increased demand for new and upgraded healthcare facilities, especially outpatient facilities, emphasizes sustainability and resilience. Updated fitness and safety rules and price range constraints necessitate value-effective, efficient layout answers. Additionally, there's robust attention on growing environments which help the sufferers and workforce properly.
The healthcare architecture market is at an upward push, pushed through elements like growing patient numbers and a focus on improving the overall level. Modern tendencies are cognizance on growing areas that might be both technologically superior and patient-centered. This method integrates features like telemedicine along with designing calming, flexible environments. Sustainability is any other massive fashion, with architects incorporating eco-friendly substances and electricity-saving functions. Overall, the healthcare architecture market is moving toward creating functional and recovery areas for the future.
Comprehensive Analysis of Healthcare Architecture Market
The healthcare architecture market is segmented with the aid of facility type and provider type. By facility type, the market includes hospitals, ASCs (Ambulatory Surgical Centers), long-term period care centers & nursing homes, educational institutes, and others. In 2023, hospitals dominated the market due to increased government efforts to enhance healthcare accessibility. ASCs are anticipated to grow substantially, driven using their value-effectiveness, decreased patient stay, and the growing prevalence of persistent diseases requiring surgical intervention. By carrier type, the market is divided into new production and refurbishment. The new production phase led the market in 2023, propelled by worldwide demand for advanced clinic architecture and large authorities funding in emerging economies.
The North American region led the medical devices market by benefitting a size of USD 2.43 billion in 2023 due to rising technological developments, growing funding for healthcare infrastructure, and the surging adoption of healthcare architecture services, nearby growth is considerably pushed.
The leading players in the healthcare architecture market significantly influence its growth trajectory and set industry standards. These key players, including HDR (U.S.), HKS Inc (U.S.), PERKINS & WILL (U.K.), Stantec (Canada), CannonDesign (U.S.), NBBJ (U.S.), Perkins Eastman (U.S.), SmithGroup (U.S.), HOK (U.S.), and EYP Architecture & Engineering (U.S.), contribute to a competitive landscape, driving innovation and market advancement.
In August 2023, HKS Inc. Announced the opening of its first workplace in Seattle, Pacific Northwest. This new workplace, devoted to era and the healthcare region, marks an expansion of the employer's existing global network of 27 places of work.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 5.1% from 2024 to 2032
Unit Value (USD Billion)
Segmentation ByFacility Type
Hospitals
ASCs
Long Term Care Facilities & Nursing Homes
Academic Institutes
Others
ByService Type
New Construction
Refurbishment
By Region
North America (By Facility Type, By Service Type, By Country)
- U.S.
- Canada
Europe (By Facility Type, By Service Type, By Country/sub-region)
- Germany
- U.K.
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Asia Pacific (By Facility Type, By Service Type, By Country/sub-region)
- India
- China
- Japan
- Australia
- Rest of Asia Pacific
Rest of the World (By Facility Type and By Service Type)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
Table of Contents
140 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of Huntington's Diseases, Key Countries/ Regions, 2022
- 4.2. Key Industry Developments (Mergers, Acquisitions, New Product Launches, etc.)
- 4.3. Pipeline Analysis, Key Players
- 4.4. Economic Cost Burden for the Treatment of Huntington's Disease, By Regions
- 4.5. Regulatory & Reimbursement Scenario, By Key Regions
- 4.6. Impact of COVID-19 on the Global Huntington’s Disease Treatment Market
- 5. Global Huntington’s Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
- 5.1. Market Analysis, Insights and Forecast – By Drug
- 5.1.1. Tetrabenazine
- 5.1.2. Deutetrabenazine
- 5.1.3. Others
- 5.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.2.1. Hospital Pharmacies
- 5.2.2. Drug Stores & Retail Pharmacies
- 5.2.3. Online Pharmacies
- 5.3. Market Analysis, Insights and Forecast – By Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Rest of the World
- 6. North America Huntington’s Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
- 6.1. Market Analysis, Insights and Forecast – By Drug
- 6.1.1. Tetrabenazine
- 6.1.2. Deutetrabenazine
- 6.1.3. Others
- 6.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.2.1. Hospital Pharmacies
- 6.2.2. Drug Stores & Retail Pharmacies
- 6.2.3. Online Pharmacies
- 6.3. Market Analysis, Insights and Forecast – By Country
- 6.3.1. U.S.
- 6.3.2. Canada
- 7. Europe Huntington’s Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
- 7.1. Market Analysis, Insights and Forecast – By Drug
- 7.1.1. Tetrabenazine
- 7.1.2. Deutetrabenazine
- 7.1.3. Others
- 7.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.2.1. Hospital Pharmacies
- 7.2.2. Drug Stores & Retail Pharmacies
- 7.2.3. Online Pharmacies
- 7.3. Market Analysis, Insights and Forecast – By Country/Sub-Region
- 7.3.1. U.K.
- 7.3.2. Germany
- 7.3.3. France
- 7.3.4. Spain
- 7.3.5. Italy
- 7.3.6. Rest of Europe
- 8. Asia Pacific Huntington’s Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
- 8.1. Market Analysis, Insights and Forecast – By Drug
- 8.1.1. Tetrabenazine
- 8.1.2. Deutetrabenazine
- 8.1.3. Others
- 8.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.2.1. Hospital Pharmacies
- 8.2.2. Drug Stores & Retail Pharmacies
- 8.2.3. Online Pharmacies
- 8.3. Market Analysis, Insights and Forecast – By Country/Sub-Region
- 8.3.1. Japan
- 8.3.2. China
- 8.3.3. India
- 8.3.4. Australia
- 8.3.5. Rest of Asia Pacific
- 9. Rest of the World Huntington’s Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
- 9.1. Market Analysis, Insights and Forecast – By Drug
- 9.1.1. Tetrabenazine
- 9.1.2. Deutetrabenazine
- 9.1.3. Others
- 9.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.2.1. Hospital Pharmacies
- 9.2.2. Drug Stores & Retail Pharmacies
- 9.2.3. Online Pharmacies
- 10. Competitive Analysis
- 10.1. Global Market Share Analysis (2022)
- 10.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
- 10.2.1. Teva Pharmaceutical Industries Ltd.
- 10.2.1.1. Overview,
- 10.2.1.2. Products,
- 10.2.1.3. SWOT Analysis,
- 10.2.1.4. Recent Developments,
- 10.2.1.5. Strategies,
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. H. Lundbeck A/S
- 10.2.2.1. Overview,
- 10.2.2.2. Products,
- 10.2.2.3. SWOT Analysis,
- 10.2.2.4. Recent Developments,
- 10.2.2.5. Strategies,
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Bausch Health Companies Inc.
- 10.2.3.1. Overview,
- 10.2.3.2. Products,
- 10.2.3.3. SWOT Analysis,
- 10.2.3.4. Recent Developments,
- 10.2.3.5. Strategies,
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Neurocrine Biosciences, Inc.
- 10.2.4.1. Overview,
- 10.2.4.2. Products,
- 10.2.4.3. SWOT Analysis,
- 10.2.4.4. Recent Developments,
- 10.2.4.5. Strategies,
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Prilenia Therapeutics
- 10.2.5.1. Overview,
- 10.2.5.2. Products,
- 10.2.5.3. SWOT Analysis,
- 10.2.5.4. Recent Developments,
- 10.2.5.5. Strategies,
- 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Novartis AG
- 10.2.6.1. Overview,
- 10.2.6.2. Products,
- 10.2.6.3. SWOT Analysis,
- 10.2.6.4. Recent Developments,
- 10.2.6.5. Strategies,
- 10.2.6.6. Financials (Based on Availability)
- 10.2.7. Lupin
- 10.2.7.1. Overview,
- 10.2.7.2. Products,
- 10.2.7.3. SWOT Analysis,
- 10.2.7.4. Recent Developments,
- 10.2.7.5. Strategies,
- 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Hikma Pharmaceuticals PLC
- 10.2.8.1. Overview,
- 10.2.8.2. Products,
- 10.2.8.3. SWOT Analysis,
- 10.2.8.4. Recent Developments,
- 10.2.8.5. Strategies,
- 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Dr. Reddy’s Laboratories Ltd.
- 10.2.9.1. Overview,
- 10.2.9.2. Products,
- 10.2.9.3. SWOT Analysis,
- 10.2.9.4. Recent Developments,
- 10.2.9.5. Strategies,
- 10.2.9.6. Financials (Based on Availability)
- 10.2.10. Sun Pharmaceutical Industries, Inc.
- 10.2.10.1. Overview,
- 10.2.10.2. Products,
- 10.2.10.3. SWOT Analysis,
- 10.2.10.4. Recent Developments,
- 10.2.10.5. Strategies,
- 10.2.10.6. Financials (Based on Availability)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
